Karyopharm Therapeutics (KPTI) Enterprise Value (2012 - 2025)

Karyopharm Therapeutics has reported Enterprise Value for 14 years, with the latest figure at -$63.7 million in Q4 2025.

• For the quarter ending Q4 2025, Enterprise Value rose 55.9% year-over-year to -$63.7 million; the trailing twelve-month figure through Dec 2025 stood at -$63.7 million (up 55.9% YoY), and the FY2025 full-year result was -$63.7 million, up 55.9% from the prior year.
• Enterprise Value for Q4 2025 stood at -$63.7 million, down from -$45.9 million in the prior quarter.
• The five-year high for Enterprise Value was -$44.5 million in Q4 2021, with the low at -$236.8 million in Q2 2023.
• Historically, Enterprise Value has averaged -$123.6 million across 5 years, with a median of -$138.7 million in 2022.
• Annual changes were most pronounced in 2022 — Enterprise Value surged 76.35% — and 2023, when it tumbled 233.84%.
• Karyopharm Therapeutics' Enterprise Value stood at -$44.5 million in 2021, then slumped by 223.21% to -$143.8 million in 2022, then tumbled by 33.09% to -$191.4 million in 2023, then increased by 24.5% to -$144.5 million in 2024, then soared by 55.9% to -$63.7 million in 2025.
• The last three Enterprise Value figures came in at -$63.7 million (Q4 2025), -$45.9 million (Q3 2025), and -$47.9 million (Q2 2025), per Business Quant data.